BioFuture 2023 took place in New York from October 4-6th, 2023. The conference included executives across numerous industries including biopharma, digital medicine, big data, artificial intelligence, healthcare systems, and insurance providers. Potential investors and partners were able to schedule one-on-one meetings with over 80 companies to discuss collaborative opportunities following the presentations.
Over the course of the conference, larger sessions for all attendees included:
- A few of the Building a Patient-Centric Healthcare System with Heart and Why It Matters
- Prescription for Progress: Healing the Ailing Healthcare System, Moving from Sickcare to Wellcare
- Supercharging Therapeutic Development: Next-Gen Technology & Therapeutic Innovation that You’ve Never Heard Of
- A Fireside Chat with Andy Plump: What Will It Take to Deliver Cures to Society
MyMD had a strong presence at the conference participating in two different speaking opportunities:
- Chris Chapman, MD, President, Director, and Chief Medical Officer discussed the overall pipeline which included three open applications with the FDA (Hashimoto’s Thyroiditis, Sarcopenia, and Rheumatoid Arthritis), shared topline data from the recently completed Phase 2 clinical trial, market opportunity, and concluded with the financials and patent portfolio.
His presentation took place on Friday on October 6th, 2023, at 9:30am EST. - Jenna Brager, PhD, Executive Vice President of Drug Development participated in a panel discussion, Longevity: Stopping Age-Related Disease at the Cellular Level. The topics ranged from how each panelist defines aging and health and if the goal is to truly reverse aging or prolong life; where each panelist foresees the aging marketing moving in 5, 10, and 15 years; and how payers, clinicians, and pharmaceuticals companies will work together to bring affordable treatments to the consumers.
This presentation took place on October 5th, 2023, at 11:45am EST.
The BioFuture attendees included but was not limited to executives from biopharma, digital medicine, AI, machine learning, generics, big data, patient advocates, professional advisors, investors, and payors – all playing an integral role in reshaping the future of healthcare. The sessions, presentations, and panels afforded the to gain valuable insights into the convergence of sectors driving better healthcare and contribute to candid discussions challenging conventional wisdom. MyMD Pharmaceuticals looks forward to attending similar conferences in 2024 to continue sharing all of its achievements in the clinical space.
Jenna Brager, PhD, RN, MS, is the Executive Vice President of Drug Development at MyMD Pharmaceuticals. Prior to joining MyMD, Dr. Brager served as the Director of Clinical Research for LifeBridge Health and was a clinical investigator at Johns Hopkins Hospital. Dr. Brager received her B.S. in Nursing from the University of North Florida, graduating cum laude and received her Ph.D. from the Johns Hopkins University School of Nursing.
Dr. Brager welcomes comments, questions, and requests for future blog topics. Please email jbrager@mymd.com.
Recent Publications:
British Society of Immunology, Liverpool, UK, December 5-8, 2022
Pharmacology and clinical profile of MYMD-1® (isomyosamine), an oral, selective, next-generation, TNF-alpha inhibitor that crosses the blood brain barrier
Authors: Jenna Brager, Ronald Christopher, Adam Kaplin, Chris Chapman
Brager J, Chapman C, Dunn L, Kaplin A. A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine Capsules in Healthy Adult Subjects. Drug Res (Stuttg). 2022 Nov 11. doi: 10.1055/a-1962-6834. Epub ahead of print. PMID: 36368677.